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Effects of interleukin-2 and interferon-ocA/D treatment on lymphocytes
from tumour-bearing mice
M. Jigo, Y. Nakajima, K. Nishikata & A. Hoshi
Chemotherapy Division, National Cancer Centre Research Institute, Tsukiji 5-chome, Chio-ku, Tokyo 104, Japan.
Summary The in vivo antitumour activities of recombinant human interleukin-2 (rHIL-2) and recombinant
human hybrid interferon alpha A/D (rIFN-aA/D) were tested in r'elation to adenocarcinoma 755. The tumour
growth, following s.c. inoculation of tumour cells, was inhibited to a greater extent in mice treated with the
combination of cytokines than in mice treated with either one alone. Pretreatment with these cytokines did
not affect the tumour growth. Injection of tumour-bearing mice with a combination of these cytokines
resulted in a marked increase in the total number of lymphocytes in the peritoneal cavity. Among them, Lyt-
2+/L3T4- and asialo GM' cells were markedly enhanced by the combination of cytokines, and the
frequencies of these marker cells were closely correlated with the antitumour activity. In tumour-bearing mice,
the size of the thymus was decreased while that of the spleen was increased compared to non-tumour-bearing
(normal) mice. Treatment with rHIL-2 caused the thymus, spleen and liver to be larger compared to
untreated tumour-bearing mice, but when treated with a combination of rHIL-2 and rIFN-aA/D these organs
were smaller than when rHIL-2 was administered alone. Thymocytes were drastically changed when mice
were bearing a tumour or were treated with a cytokine. Especially immature T-cells, Lyt-2+/L3T4+, were
drastically decreased in tumour-bearing mice, but were maintained following administration of rHIL-2 or
rIFN-aA/D. When treated with rHIL-2 plus rIFN-aA/D, Lyt-2+/L3T4+ T-cells were decreased while Lyt-2+/
L3T4- T-cells were increased. Frequency of immature T-cells, Lyt-2-/L3T4-, was not changed. On the other
hand, T-cell subsets of splenocytes were markedly decreased in tumour-bearing mice compared to normal
mice, but all the subsets of splenocytes were almost unchanged even when tumour-bearing mice were treated
with rHIL-2 plus rIFN-aA/D. Thus, injection of rHIL-2 and rIFN-aA/D to tumour-bearing mice resulted in
induction of Lyt-2+/L3T4- and asialo GM1+ cells in the peritoneal cavity, and the frequencies correlated
with the observed antitumour activity in vivo in this murine model. The increase in Lyt-2+/L3T4- T-cells in
the peritoneal cavity may be related to changes in the T-cells in thymus.
IL-2 promotes in vitro growth of mature T-lymphocyte
(Morgan et al., 1976; Smith, 1980). The proliferation results
from interaction with a specific cell membrane receptor (IL-
2R), which is absent from resting T-cells (Hardt et al., 1987).
The thymus is regarded as the primary site for differentiation
of T-lymphocytes (Metcalf, 1966). However, the majority of
in vivo activated T-cells in the thymus do not express IL-2R
(Ceredig et al., 1985; Lugo et al., 1985). Moreover, injection
of IL-2 in vivo does not induce proliferation of mature T-
lymphocytes but increases production of haemopoietic and
NK cells (Piguet et al., 1986).
Combination therapy with human recombinant IL-2
(rHIL-2) and human recombinant interferon-aA/D (rIFN-
ocA/D) or murine recombinant interferon-fl (rIFN-f)
produces marked retardation of tumour growth, and
repeated treatment can lead to cure (Iigo et al., 1986, 1988;
Brunda et al., 1987). In animals treated in vivo with anti-
asialo GM1 antibody or in NK-deficient beige mice, the
potentiation did not decrease (Iigo et al., 1986, 1988).
However, the tumour inoculated in athymic mice is not
caused to regress by the combination of rHIL-2 and rIFN
(ligo et al., 1986), suggesting that the mechanism of tumour
regression caused by combination of rHIL-2 and rIFN
appears to involve T-cell maturation. T-lymphocytes were
characterised by using the subsets of Lyt-2 and L3T4, and
then we examined the subsets of lymphocytes in the
peritoneal cavity, thymus and spleen of tumour-bearing mice
after repeated injection with rHIL-2 and/or rIFN-aA/D by
flow cytometry. We also examined for correlations between
the subsets and the antitumour activity.
Materials and methods
Animals
Inbred, 5-week-old, male C57BL/6 mice of approximately
22g body weight were obtained from the Shizuoka
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Laboratory Animal Centre (Hamamatsu, Japan). Each group
consisted of 6-8 mice. These were maintained under specific-
pathogen-free conditions in our laboratory. All experiments
were initiated when the mice were 7 weeks old.
Tumour
Adenocarcinoma 755 (5 x 105 cells per mouse) was implanted
s.c. into the right hind legs of the mice, causing an s.c.
tumour nodule to appear at the inoculation site in all
animals on day 5.
Cytokines and treatments
Lyophilised rHIL-2 (specific activity: 1 x 107 Umg 1 protein
was kindly supplied by Biogen SA, Switzerland, and
Shionogi & Co., Osaka, Japan. rIFN-axA/D, which is a
hybrid molecule of A and D clone DNAs, was generously
provided by Nippon Roche Research Center, Kamakura,
Japan (specific activity: 2.04 x 107 IUml-1).
When the tumours became palpable (about 5mm
diameter), rHIL-2 and rIFN-aA/D were administered i.p. or
s.c. (left thigh) at doses of 105 units per mouse and 105 IU
per mouse, respectively, and this was continued daily for a
period of 9 days.
Monoclonal antibodies (mAb)
Four different rat mAb specific for T-cell surface antigens
were used: IgG2b anti-Thy-1.2 (mAb 30H12), IgG2. anti-
Lyt-I (mAb 53.7.3), IgG2a anti-L3T4 (mAb GK 1.5) and
IgG2a anti-Lyt-2 (mAb 53.6.7) were purchased from Becton
Dickinson (Mountain View, CA, USA). IgG2b murine/
human anti-Mac-I (M1/70), IgG2b anti-Ia (M5/114) and
anti-asialo GM1 were purchased from Hybritech Inc. (San
Diego, CA, USA) and Wako Pure Chemical Industries
(Osaka, Japan), respectively. For a flow cytometric analysis,
anti-Mac-i, anti-Ia and anti-asialo GM1 were used together
with fluorescein isothiocyanate (FITC)-coupled anti-rat and
anti-rabbit Ig antibodies, respectively.
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Lymphocyte subset analysis
Organ studies were performed 6h after the ninth daily i.p. or
s.c. injection of cytokines. The mice were killed by cervical
dislocation, 10ml of 0.9% saline solution was injected i.p.
and, after gentle lavage, the peritoneal contents were taken.
The peritoneal contents obtained from three mice were
pooled, washed to remove cell debris, suspended in 5ml of
Cytotoxicity Medium containing 0.3% fetal calf serum
(Cedarlane Laboratories Ltd, Ontario, Canada) and stored
on ice (three mice per group). The tumour, spleen and
thymus were rapidly removed, weighed and stored on ice (six
mice per group). The spleen and thymus were minced with
scissors in separate Petri dishes containing 5 ml of
Cytotoxicity Medium and pressed through a wire mesh (120
mesh). The cells obtained were pooled with 15ml of medium
on ice. For single-colour analysis, fluorescein-labelled mAb
was added to cell suspensions in tubes (1 x 105 cells per
0.1 ml) at 4°C for 30min, and FACS lysing solution (Becton
Dickinson, Mountain View, CA, USA) was added for
10min. After centrifugation, saline (1 ml) was added and
5,000-20,000 cells from each suspension were analysed by
flow cytometry (Spectrum III, Ortho Diagnostic System Inc.,
Mass., U.S.A.). For two-colour analysis, cells were incubated
with fluorescein phycoerythrin (PE)-conjugated anti-L3T4
plus fluorescein (FITC)-conjugated anti-Lyt-2. The propor-
tions of Lyt-2+/L3T4-, Lyt-2-/L3T4+ and Lyt-2+/L3T4+
T-cells were determined directly as percentages. The propor-
tion of Lyt-2-/L3T4- T-cells was calculated as the differ-
ence between the percentage of Thy-1.2+ cells and the sum
of the percentages of L3T4+ and Lyt-2+ minus Lyt-2+/
L3T4+ cells (Ermak et al., 1988). The number of specific
lymphocytes was calculated from the frequency of the speci-
fic lymphocyte and the number of total lymphocytes in the
peritoneal cavity.
Data analysis
The reported results are the average of experiments
performed at least in duplicate under identical conditions.
Student's t test was used to determine statistical significance.
Results
Effect of combinations of rHIL-2 and rIFN-aA/D on s.c.
tumour growth
Using s.c. inoculated adenocarcinoma 755, we examined
potentiation of the antitumour effects of rHIL-2 and rIFN-
cxA/D. Daily treatment of mice with the cytokines alone or
in combination was initiated on day 7 and continued until
day 15. Treatment with either cytokine alone caused no
significant reduction in tumour size as measured by the
tumour weight at the termination of the experiment (day 15).
However, combined treatment of mice with rHIL-2 and
rIFN-aA/D, both cytokines injected i.p. or s.c., resulted in a
substantial reduction in tumour size, but when one cytokine
was injected i.p. and the other s.c., the potency of synergism
became weaker (Table I). Thus, when the combination of
rHIL-2 and rIFN-axA/D was simultaneously injected to
tumour-bearing mice, marked regression of the tumour was
produced. However, when normal mice were pretreated with
rHIL-2 plus rIFN-oaA/D for 8 days and then the tumour
cells were inoculated on day 9, the tumour growth was not
affected by any of the treatments. Therefore, we investigated
lymphocytes in tumour-bearing mice.
Effect of combination of rHIL-2 and rIFN-axA/D on thymus,
spleen and liver
The combination of cytokines markedly inhibited tumour
growth. At that time, we first measured the organ weights to
see the effects of the cytokines on the lymphoid organs: the
thymus, spleen and liver. The thymus of the tumour-bearing
mice (day 15) was markedly smaller than that of normal
mice. When rHIL-2 was administered to tumour-bearing
mice, the thymus was significantly larger than in untreated
tumour-bearing mice. However, when the cytokines were
combined, the thymus became significantly smaller than with
rHIL-2 alone (Table II). On the other hand, the spleen of
tumour-bearing mice was markedly larger than in normal
mice. Moreover, after rHIL-2 treatment the spleen was
larger than in untreated tumour-bearing mice, but after the
combination of rHIL-2 and rIFN-oaA/D the spleen was
significantly smaller than with rHIL-2 alone. Furthermore,
the liver weight after treatment with these cytokines was
affected similarly to the spleen. Thus, the thymus, spleen and
liver weights were affected by treatment with the cytokines,
and there were marked differences between use of one
cytokine alone and use of a combination of the cytokines.
Table I Effect of rHIL-2 and rIFN-ocA/D on adenocarcinoma 755
tumour growtha
Tumour
No. of weight (mg) TIC
Treatment animals mean+s.e. (%)
Control 12 4,805+ 133
rHIL-2 (i.p.) 12 3,776+223 79
rIFN-aA/D (i.p.) 12 3,805+197 79
rHIL-2 (i.p.)+rIFN-aA/D (i.p.) 12 1,330+230b 28
rHIL-2 (i.p.)+rIFN-acA/D (s.c.) 6 1,848+140b 38
rHIL-2 (s.c.)+rIFN-oA/D (s.c.) 6 762+122b 16
aC57BL/6 mice were injected s.c. with 5 x 105 adenocarcinoma 755
cells on day 0. Treatments i.p. or s.c. daily were initiated on day 7
and continued until day 15. Doses of rHIL-2 and rIFN-
aA/D were 105U per mouse and 10 IU per mouse, respectively.
Mice were killed on day 15. S.c. tumours were excised and weighed;
bp<0.001 compared to rHIL-2 or rIFN-aA/D treatment group.
Table II Effect of rHIL-2 and rIFN-aA/D on thymus, spleen and liver weight
No. of Wet weight (mg)b
Treatment' animals Thymus Spleen Liver
Normal mice 18 52+3 65+ 4 1,080+47
Tumour-bearing mice 12 14+2 330+ 18 1,183+62
rHIL-2 (i.p.) 12 24+2c 391+18d 1,912+41c
rIFN-xA/D (i.p.) 12 19+2 337+12 1,470+3ld
rHIL-2 (i.p.)+rIFN-cxA/D (i.p.) 12 17+ le 229+ 12e 1,537+59e
rHIL-2 (i.p.)+rIFN-aA/D (s.c.) 6 19+2' 244+ 14e 1,692+91
rHIL-2 (s.c.)+rIFN-aA/D (s.c.) 6 12+1 177+ 49 1,238+68
aTumour-bearing mice were injected rHIL-2 and/or rIFN-aA/D i.p. or s.c. on days
7-15. Doses of rHIL-2 and rIFN-aA/D were 105 U per mouse and 105 IU per mouse,
respectively; bMice were killed on day 15, and thymus, spleen and liver were excised
and weighed. Mean+s.e.; CP<0.001 compared to tumour-bearing mice group;
dp<0.05 compared to tumour-bearing mice group; eP<0.01 compared to rHIL-2
treatment group; fP<0.05 compared to rHIL-2 treatment group; 9P<0.001 compared
to rHIL-2 treatment group.IL-2 AND IFN-aA/D 885
Changes in lymphocyte subsets in peritoneal cavity of
tumour-bearing mice after treatment with rHIL-2 and
rIFN-axA/D
In vivo studies (Iigo et al., 1986, 1988) suggest that one of
the effector cells causing regression of the tumour is
cytotoxic T-lymphocytes (CTL). In in vitro study, there is no
difference in the augmentation of cytokine activity against
YAC-1 in the splenic effector cells between treatment with
rHIL-2 alone and combination of rHIL-2 and rIFN (ligo et
al., 1988). We then studied the T-cell subsets in lymphoid
organs following administration of cytokines. Lymphocytes
possess Lyt-antigenic phenotypes which are characteristic of
helper T-cells (Lyt-2-/L3T4+) and CTL (Lyt-2+/L3T4-).
Lyt-antigenic phenotypes could therefore be of use in charac-
terising the effector-cell for rHIL-2 and rIFN. First, we
studied whether the lymphocytes in the peritoneal cavity
were increased and their phenotypes were changed following
treatment with cytokines by i.p. or s.c. flow cytometric
analysis of responding lymphocytes in the peritoneal cavity
tested for the presence of specific lymphocyte subpopulations
defined by the monoclonal antibodies Thy-1.2, Lyt-1, L3T4,
Lyt-2, Mac-1, asialo GM1 and Ia. There were marked
differences between non-tumour-bearing (normal) and
tumour-bearing mice; the frequencies of Lyt-l+ and Lyt-2+
cells in tumour-bearing mice were higher than in normal
mice, but Mac-i+ and asialo GM1 + and Ta+ cells were less
than in normal mice (Table III). The total cell number of T-
cells (Thy-1.2+, Lyt-l +, L3T4+, Lyt-2+) in tumour-bearing
mice was markedly increased compared to normal mice.
When rHIL-2 was administered to tumour-bearing mice, the
total lymphocytes were increased and the frequencies (%) of
Thy-1.2+, L3T4+, Lyt-2+, Mac-I+, asialo GM,+ and Ia+
marker cells were markedly increased. Total lymphocytes
following rIFN-aA/D were not increased compared to
tumour-bearing mice, but frequencies of Thy-1.2+ and asialo
GM1+ marker cells were markedly increased. Total lympho-
cytes following administration of rHIL-2 plus rIFN-ocA/D
(except for the combination of s.c. rHIL-2 and s.c. rIFN-
aA/D) were markedly increased (about 3-fold compared to
tumour-bearing mice), and the frequencies of Thy-1.2+, Lyt-
i+, L3T4+, Lyt-2+, Mac-I+ and asialo GM1 + cells were
markedly increased. In particular the combination of rHIL-2
and rIFN-ocA/D increased the percentage of cells expressing
the Lyt-2+ marker from 12 to 40%, in contrast to the
frequency of Ta+ cells, which are thought of as B cell
markers, which was decreased by this combination. The
frequency of Lyt-2+/L3T4+ cells in the peritoneal cavity was
less than 1.5%. Moreover, the antitumour activity of cyto-
kines correlated closely with the frequency (%) of Lyt-2+
cells (r=0.91, P<0.01) and asialo GM1 + cells (r=0.944,
P<0.01).
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L3T4+ cells (22 vs 40%). On the other hand, Lyt-2+/L3T4+
cells (less than 10%) were markedly decreased by the
combination of rHIL-2 and rIFN-aA/D compared to either
cytokine alone. Moreover, in the combination of i.p. rHIL-2
and i.p. rIFN-aA/D or s.c. rHIL-2 and s.c. rIFN-aA/D,
which showed a marked antitumour effect, frequency of Lyt-
2+/L3T4- cells was also enhanced. However, the frequency
of Lyt-2-/L3T4- T-cells was not changed following treat-
ment with cytokines. Lymphocytes expressing the Ta
specificity were found in greater frequency in rHIL-2 or
rIFN-aA/D treatment (26 vs 50-70%), but in the
combinations of rHIL-2 and rIFN-aA/D Ia' cells decreased
to the same level as normal mice (about 30%). Thus, Ta'
cells showed changes similar to Lyt-2+/L3T4+ T-cells.
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On the other hand, all the T-cell surface markers of
splenocytes in the tumour-bearing mice were decreased
compared to normal mice, and only asialo GM1 marker cells
were increased. There were no marked differences in surface
markers between treatment with cytokine alone and their
combination (Figure 2).
Discussion
Combination of rHIL-2 and rIFN-aA/D markedly enhances
the antitumour effect compared to cytokine alone, and
repeated treatment results in some cases of cure in mice (Iigo
et al., 1988). This enhanced antitumour effect is not reduced
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Figure 1 Flow cytometric analysis of lymphocytes in the thymus of tumour-bearing mice after treatments of rHIL-2 and rIFN-
ocA/D. rHIL-2 (l05U per mouse) and rIFN-aA/D (105IU per mouse) were administered to tumour-bearing mice on days 7-15.
The mice were killed 6h after last treatment and the thymus was taken. Mean+s.e. of three or two experiments (six mice per
group).
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in animals treated in vivo with anti-asialo GM1 antibody or
in NK-deficient beige mice (ligo et al., 1986, 1988).
Moreover, pretreatment with cytokines did not affect tumour
growth. However, a tumour inoculated into athymic mice
does not regress in this combination (ligo et al., 1986),
suggesting that the tumour regression achieved by rHIL-2
plus rIFN-aA/D involves T-cell maturation. A necessary
condition for the in vivo activation in this combination was
simultaneous daily administration (more than eight times) of
cytokines into the peritoneal cavity or subcutaneously to
tumour-bearing mice. The count of lymphocytes detectable
in the peritoneal cavity following treatment with rHIL-2 plus
rIFN-acA/D was 3-fold higher than in untreated tumour-
bearing mice. Thymus of adenocarcinoma 755-bearing mice
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(day 15) became too small and spleen too large. When rHIL-
2 was administered to tumour-bearing mice, the weights of
the thymus, spleen and liver became significantly higher than
in untreated tumour-bearing mice. When rHIL-2: was
administered together with rIFN-aA/D, the thymus, spleen
and liver weight became smaller than when rHIL-2 was
administered alone. These phenomena indicate that cytokines
directly or indirectly affect these lymphoid organs.
rHIL-2 potentiates both the growth and cytotoxic function
of T-lymphocytes and NK cells (Lanier et al., 1988).
However, Piguet et al. (1986) reported that rHIL-2 treatment
in vivo did not induce proliferation ofmature T-lymphocytes.
IFN can act as a CTL differentiation signal (Chen et al.,
1986). The count of lymphocytes in the peritoneal cavity was
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increased following treatment with rHIL-2 plus rIFN-aA/D.
Among them, the frequency of cells expressing the Lyt-2
marker was increased from 12 to 36-40%. And the
frequency of Lyt-2+/L3T4- marker cells was closely
correlated with antitumour effect (r=0.97), and asialo GM1
marker cells also showed a positive correlation with the
antitumour effect (r=0.94). Moreover, in Winn assays
(submitted), progressive tumour growth was completely
prevented by peritoneal cells from tumour-bearing mice
treated with rHIL-2 plus rIFN, but elimination of Thy-I',
Lyt-2+ or asialo GM1+ cells by mAb and complement
abolished the protective capacity of the immune peritoneal
cells. Therefore, there is a possibility that the effector cells
may be large mononuclear leukocytes with Thy-1.2+, Lyt-
2+, L3T4- and asialo GM1+ (Piguet et al., 1986).
The host defence mechanism in the presence of a tumour
may be responsible for augmentation of the frequencies of T-
cells because Lyt-2-/L3T4+ (helper) and Lyt-2+/L3T4-
(CTL) were increased in thymus of tumour-bearing mice.
Although the pathway by which helper T-cells and CTL
develop from immature precursors within the thymus is
largely obscure, treatment with cytokines markedly changed
the T-cell markers. rHIL-2 or rIFN-aA/D maintained large
percentages of Lyt-2+/L3T4+ immature T-cells in the
thymus without any effect of tumour-bearing, but immature
Lyt-2-/L3T4- T-cells were not increased. In the case of
combination of rHIL-2 and rIFN-aA/D, Lyt-2+/L3T4+ cells
were decreased and Lyt-2+/L3T4- cells were increased
similar to the lymphocytes in the peritoneal cavity. Thus, the
frequency of Lyt-2+/L3T4+ immature T-cells was more than
90% in the thymus of normal mice but only 20% in tumour-
bearing mice (advanced tumour). If rHIL-2 or rIFN-aA/D
was injected into tumour-bearing mice, Lyt-2+/L3T4+ cells
were 40-50%, but if rHIL-2 was injected together with
rIFN-aA/D, Lyt-2+/L3T4+ cells were drastically decreased
to 2-10%. This evidence suggests that Lyt-2+/L3T4+
immature T-cells may be important to generate mature Lyt-
2+ cells. It is known that Lyt-2-/L3T4- T-cells are
important to produce mature T-cells (Raulet, 1985;
Lowenthal et al., 1988). Maybe the combination of rHIL-2
and rIFN-aA/D promotes formation of mature T-
lymphocytes (Lyt-2+/L3T4-) from immature T-
lymphocytes (Lyt-2-/L3T4-) in the thymus.
Recently, Brunda et al., (1987) reported that the
combination of rHIL-2 and rIFN-aA/D showed a synergic
antitumour effect by the induction of an NK-cell-like
population. Cameron et al. (1988) reported that the
combination of rHIL-2 and rIFN-aA/D showed significant
reductions in the number of MCA-106 liver metastases
compared to cytokine alone and Rosenberg et al. (1988) also
reported that this synergy was dependent on Lyt-2+ T-cells.
Although we have no evidence of NK cells being
responsible for the regression of tumours, combined
treatment with rHIL-2 and rIFN can induce large numbers
of Lyt-2+/L3T4- and asialo GM1 + cells. The enhanced
antitumour effect may be due to an increase in the number
of active Lyt-2+/L3T4- and asialo GM1 + cells at the tumour
site.
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